文献速递运动医学关节外科

桥增强前交叉韧带修复在2年时非劣于自体肌腱前交叉韧带重建:前瞻性随机临床试验结果

Bridge-Enhanced Anterior Cruciate Ligament Repair Is Not Inferior to Autograft Anterior Cruciate Ligament Reconstruction at 2 Years: Results of a Prospective Randomized Clinical Trial.
PubMed 文献 · Am J Sports Med · 2020-04-16

BACKGROUND: Preclinical studies suggest that for complete midsubstance anterior cruciate ligament (ACL) injuries, a suture repair of the ACL augmented with a protein implant placed in the gap between the torn ends (bridge-enhanced ACL repair [BEAR]) may be a viable alternative to…

要点

  • BEAR在2年时IKDC主观评分和前后向膝关节松弛度均非劣于自体肌腱ACLR。
  • BEAR组2年腘绳肌力量指数显著高于ACLR组(98.2% vs 63.2%,P < .001)。
  • 两组再损伤需同侧二次ACL手术的比例分别为14%和6%(P = .32),差异无统计学意义。

核心结论

  • 在年轻活跃人群中,BEAR在2年随访时患者报告结局和前后向膝关节松弛度非劣于自体肌腱ACLR,且腘绳肌力量更优。

研究设计与样本

  • 患者中位年龄17岁,中位术前Marx活动评分16,均在伤后45天内接受手术。
  • 2年时由对手术方式设盲的独立检查者评估结局,患者2年访视后揭盲。

主要发现

  • 96%的患者完成2年随访。
  • IKDC主观评分:BEAR组88.9分,ACLR组84.8分,平均差异4.1分(95% CI,-1.5至9.7),达到预设非劣效界值-11.5分。
  • 前后向膝关节松弛度侧侧差:BEAR组1.61 mm,ACLR组1.77 mm,平均差异-0.15 mm(95% CI,-1.48至1.17),达到预设非劣效界值+2 mm。
  • 2年腘绳肌力量指数:BEAR组98.2%,ACLR组63.2%,P < .001。
  • 再损伤需同侧二次ACL手术:BEAR组14%,ACLR组6%,P = .32。

关键数值与推荐

  • IKDC主观评分预设非劣效界值为-11.5分。
  • 前后向膝关节松弛度侧侧差预设非劣效界值为+2 mm。

临床怎么用

  • 对于完全中段ACL损伤的年轻活跃患者,BEAR可作为自体肌腱ACLR的替代选择,但需注意再损伤需二次手术的比例在数值上较高(14% vs 6%,P = .32)。
  • BEAR术后腘绳肌力量保留优于自体腘绳肌腱ACLR。

局限性

  • 样本量较小(BEAR组65例,ACLR组35例),再损伤等次要结局的统计效能有限。
  • 随访时间仅2年,长期疗效和再损伤风险尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical studies suggest that for complete midsubstance anterior cruciate ligament (ACL) injuries, a suture repair of the ACL augmented with a protein implant placed in the gap between the torn ends (bridge-enhanced ACL repair [BEAR]) may be a viable alternative to ACL reconstruction (ACLR). HYPOTHESIS: We hypothesized that patients treated with BEAR would have a noninferior patient-reported outcomes (International Knee Documentation Committee [IKDC] Subjective Score; prespecified noninferiority margin, -11.5 points) and instrumented anteroposterior (AP) knee laxity (prespecified noninferiority margin, +2-mm side-to-side difference) and superior muscle strength at 2 years after surgery when compared with patients who underwent ACLR with autograft. STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: One hundred patients (median age, 17 years; median preoperative Marx activity score, 16) with complete midsubstance ACL injuries were enrolled and underwent surgery within 45 days of injury. Patients were randomly assigned to receive either BEAR (n = 65) or autograft ACLR (n = 35 [33 with quadrupled semitendinosus-gracilis and 2 with bone-patellar tendon-bone]). Outcomes-including the IKDC Subjective Score, the side-to-side difference in instrumented AP knee laxity, and muscle strength-were assessed at 2 years by an independent examiner blinded to the procedure. Patients were unblinded after their 2-year visit. RESULTS: In total, 96% of the patients returned for 2-year follow-up. Noninferiority criteria were met for both the IKDC Subjective Score (BEAR, 88.9 points; ACLR, 84.8 points; mean difference, 4.1 points [95% CI, -1.5 to 9.7]) and the side-to-side difference in AP knee laxity (BEAR, 1.61 mm; ACLR, 1.77 mm; mean difference, -0.15 mm [95% CI, -1.48 to 1.17]). The BEAR group had a significantly higher mean hamstring muscle strength index than the ACLR group at 2 years (98.2% vs 63.2%; P < .001). In addition, 14% of the BEAR group and 6% of the ACLR group had a reinjury that required a second ipsilateral ACL surgical procedure (P = .32). Furthermore, the 8 patients who converted from BEAR to ACLR in the study period and returned for the 2-year postoperative visit had similar primary outcomes to patients who had a single ipsilateral ACL procedure. CONCLUSION: BEAR resulted in noninferior patient-reported outcomes and AP knee laxity and superior hamstring muscle strength when compared with autograft ACLR at 2-year follow-up in a young and active cohort. These promising results suggest that longer-term studies of this technique are justified. REGISTRATION: NCT02664545 (ClinicalTrials.gov identifier).

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Murray MM, Fleming BC, Badger GJ, et al. Bridge-Enhanced Anterior Cruciate Ligament Repair Is Not Inferior to Autograft Anterior Cruciate Ligament Reconstruction at 2 Years: Results of a Prospective Randomized Clinical Trial. Am J Sports Med. 2020. PMID: 32298131. doi:10.1177/0363546520913532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。